Ann: USCOM Recognised by China National ICU Society, page-6

Realistically UCM needs runs on the board with results. The last half yearly was fantastic and it was a shame that the last quarterly couldn't build on it.

That being said, the disappointment was caused a delay in Chinese FDA approval and Chinese New Year slowing sales. This quarter will have a full quarter of Chinese sales, and this announcement to help marketing efforts.

Combine that with the R&D tax refund and the headline figures in the next quarterly should read well. That will hopefully be the spark we need.

It is also good timing for an investor presentation, and I wouldn't be opposed to a cap raising if it was needed to fund extra manufacturing for Chinese expansion. Preferably it would be a rights issue for existing holders, I've never been a fan of placements to institutions even if it is cheaper and easier.

I am happy for UCM to remain under the radar for now. It is a very illiquid stock and can be hard to get a position. I would still like to purchase more before a re-rate occurs.